Checkpoint Therapeutics Inc (NASDAQ: CKPT)’s stock price has dropped by -3.88 in relation to previous closing price of 3.35. Nevertheless, the company has seen a loss of -9.04% in its stock price over the last five trading days. seekingalpha.com reported 2024-12-18 that Checkpoint Therapeutics, Inc. received FDA approval for Unloxcyt, the first PD-L1 drug for advanced cSCC, with strong clinical results and a market-disruptive pricing strategy. Despite mixed investor reactions, Unloxcyt’s potential $1.6B peak sales and competitive pricing could make it a transformative player in the cSCC market. Risks include high competition, commercialization costs, and potential IP challenges, but Checkpoint’s strategic partnerships and marketing are crucial for success.
Is It Worth Investing in Checkpoint Therapeutics Inc (NASDAQ: CKPT) Right Now?
The 36-month beta value for CKPT is at 1.35. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CKPT is 40.38M, and currently, shorts hold a 16.88% of that float. The average trading volume for CKPT on December 31, 2024 was 1.38M shares.
CKPT’s Market Performance
The stock of Checkpoint Therapeutics Inc (CKPT) has seen a -9.04% decrease in the past week, with a -26.65% drop in the past month, and a 47.03% gain in the past quarter. The volatility ratio for the week is 7.37%, and the volatility levels for the past 30 days are at 10.66% for CKPT. The simple moving average for the past 20 days is -13.45% for CKPT’s stock, with a 30.26% simple moving average for the past 200 days.
Analysts’ Opinion of CKPT
Many brokerage firms have already submitted their reports for CKPT stocks, with B. Riley Securities repeating the rating for CKPT by listing it as a “Buy.” The predicted price for CKPT in the upcoming period, according to B. Riley Securities is $7 based on the research report published on July 14, 2022 of the previous year 2022.
B. Riley Securities, on the other hand, stated in their research note that they expect to see CKPT reach a price target of $18. The rating they have provided for CKPT stocks is “Buy” according to the report published on June 09th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to CKPT, setting the target price at $16 in the report published on January 20th of the previous year.
CKPT Trading at -11.64% from the 50-Day Moving Average
After a stumble in the market that brought CKPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.44% of loss for the given period.
Volatility was left at 10.66%, however, over the last 30 days, the volatility rate increased by 7.37%, as shares sank -23.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.30% upper at present.
During the last 5 trading sessions, CKPT fell by -7.06%, which changed the moving average for the period of 200-days by +71.35% in comparison to the 20-day moving average, which settled at $3.72. In addition, Checkpoint Therapeutics Inc saw 40.61% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CKPT starting from Oliviero James F III, who sale 602,167 shares at the price of $3.87 back on Dec 18 ’24. After this action, Oliviero James F III now owns 3,414,813 shares of Checkpoint Therapeutics Inc, valued at $2,330,386 using the latest closing price.
Oliviero James F III, the CEO, President and Director of Checkpoint Therapeutics Inc, sale 220,230 shares at $3.38 during a trade that took place back on Dec 19 ’24, which means that Oliviero James F III is holding 3,194,583 shares at $744,377 based on the most recent closing price.
Stock Fundamentals for CKPT
Current profitability levels for the company are sitting at:
- -798.17 for the present operating margin
- -451.68 for the gross margin
The net margin for Checkpoint Therapeutics Inc stands at -988.68. The total capital return value is set at 2.98.
Currently, EBITDA for the company is -52.15 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 3177.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.29.
Conclusion
In conclusion, Checkpoint Therapeutics Inc (CKPT) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
